Home Featured Page 4

Featured

Latest

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions

AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal

Pα+ Psychedelic Bulletin #219: Trump Admin. Vetoed Compass Priority Voucher; Ibogaine...

Center for MINDS: Bruce Damer on Why We Need Psychedelic-Catalysed Innovation

The Psychedelic News Feed: January 26 – Febraury 1, 2026

Q3 2025: Oregon Psilocybin Services Update

Patient Safety After a Death: What Transparency Can and Cannot Do

January 2026 Psychedelic Bill Round-up

The Psychedelic News Feed: January 19 – 25, 2025

“Changes Are Never Linear”: Joost Breeksema on the Human Side of...

Op-Ed: From Psychedelic Prohibition to Psychedelic Public Health

Pα+ Psychedelic Bulletin #218: FDA’s Farchione Says Psychedelic INDs Are “a...

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions

AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal

Pα+ Psychedelic Bulletin #219: Trump Admin. Vetoed Compass Priority Voucher; Ibogaine...

Center for MINDS: Bruce Damer on Why We Need Psychedelic-Catalysed Innovation

The Psychedelic News Feed: January 26 – Febraury 1, 2026

Q3 2025: Oregon Psilocybin Services Update

Patient Safety After a Death: What Transparency Can and Cannot Do

January 2026 Psychedelic Bill Round-up

The Psychedelic News Feed: January 19 – 25, 2025

“Changes Are Never Linear”: Joost Breeksema on the Human Side of...

Op-Ed: From Psychedelic Prohibition to Psychedelic Public Health

Pα+ Psychedelic Bulletin #218: FDA’s Farchione Says Psychedelic INDs Are “a...

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY